# The effect of dienogest and gonadotropin-releasing hormone agonist on pelvic pain after laparoscopic surgery for endometriosis: An RCT

**Authors:** Fatemeh Davari Tanha, Azam Rasti, Hamideh Pakniat, Shohreh Salimi Setudeh

PMC · DOI: 10.18502/ijrm.v22i12.18065 · International Journal of Reproductive Biomedicine · 2025-01-31

## TL;DR

This study compared dienogest and GnRH agonists for reducing pelvic pain after endometriosis surgery, finding similar pain relief but different side effects.

## Contribution

A randomized clinical trial comparing the efficacy and adverse effects of dienogest and GnRH agonists in managing post-surgical pelvic pain in endometriosis patients.

## Key findings

- Both dienogest and GnRH agonists significantly improved pelvic pain after 3 months.
- GnRH agonists and dienogest caused different adverse effects, such as vaginal dryness and decreased libido.
- Both drugs reduced irregular vaginal bleeding.

## Abstract

Endometriosis is a chronic inflammatory condition associated with debilitating chronic pelvic pain that affects women's quality of life. Several drugs have been used to reduce pain and psychological distress associated with this disease. Currently, gonadotropin-releasing hormone (GnRH) agonists and dienogest are the most widely used medical therapies for endometriosis.

This study aimed to investigate the efficacy of dienogest and GnRH agonists in improving pelvic pain after laparoscopic surgery for endometriosis.

In this randomized clinical trial study, 104 women with endometriosis who were referred to the Department of Reproductive Medicine of Yas hospital, Tehran, Iran, between April 2022 and March 2023 were studied. After laparoscopic surgery, individuals were randomly assigned into 2 groups (n = 52/each): the dienogest-administered group and the GnRH agonist-administered group. Participants were followed up at 3 months and pelvic pain was measured using the visual analog scale. Pelvic pain and adverse effects of drugs were compared between the groups.

Pelvic pain significantly improved in both treatment groups (p 
<
 0.0001). No significant difference was observed in hot flashes and joint pain between the dienogest and GnRH agonist groups. However, a significant difference was found in vaginal dryness (p = 0.03) and decreased libido (p = 0.02). GnRH agonists and dienogest reduced irregular vaginal bleeding.

Our results suggested that the effect of GnRH agonists and dienogest in improving pelvic pain for endometriosis is the same after a 3-month treatment period. However, these 2 drugs caused different adverse effects.

## Linked entities

- **Chemicals:** dienogest (PubChem CID 68861)
- **Diseases:** endometriosis (MONDO:0005133)

## Full-text entities

- **Diseases:** vaginal bleeding (MESH:D014592), joint pain (MESH:D018771), Pelvic pain (MESH:D017699), hot flashes (MESH:D019584), pain (MESH:D010146), Endometriosis (MESH:D004715), vaginal dryness (MESH:D014627)
- **Chemicals:** GnRH agonist (-), dienogest (MESH:C023635)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11830921/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC11830921/full.md

## References

26 references — full list in the complete paper: https://tomesphere.com/paper/PMC11830921/full.md

---
Source: https://tomesphere.com/paper/PMC11830921